Dietary intake, energy availability and weight control practices of male apprentice jockeys residing at the SA Jockey Academy

MSc (Nutrition), North-West University, Potchefstroom Campus, 2015INTRODUCTION: Professional jockeys are considered elite sportsmen competing in a sport with certain weight restrictions. Horse racing is categorized as a “weight-making” sport where jockeys can benefit from attaining and/or maintaining a specific weight for competition. The minimum riding weight for professional jockeys and apprentice jockeys who are race riding is currently 52 kg. The lighter the jockey (i.e. the closer he can remain to the minimum weight of 52 kg) the more rides may be allocated to him (and the more money he will earn). This places a great deal of pressure on the jockey to maintain a low body weight, in order to attain rides. Unlike other weight category sports, horse riding does not have an “off season”, therefore jockeys are constantly pressured to maintain a minimal weight. Consequently this may result in unhealthy eating habits, dangerous weight control practices and compromised health. Research on the weight making practices of apprentice jockeys is scarce. In fact, there is currently no published data available on the South African apprentice jockey. The aim of this study was therefore to examine the dietary intake, energy availability and weight control practices of male apprentice jockeys residing at the South African Jockey Academy. METHODS: Twenty one male flat jockey apprentices of different race groups, between the ages of 16 and 20 years were recruited to take part in this cross sectional observational study. Height, weight and body composition (body fat percentage and fat free mass) were measured. The apprentices completed a 59-item nutrition, health and lifestyle questionnaire including questions on weight control and weight making practices. Dietary intake was recorded with a 24-hour dietary recall on four non-consecutive days including a rest day, two training days, and a race day. On these days, exercise energy expenditure was also recorded with Actiheart© monitors with the aim to calculate energy availability. MAIN FINDINGS: Total mean reported energy intake of the participants was 7088±2337kJ (35.5±12.5kcal/kg fat free mass [FFM]) and below the recommendations for athletes exercising several hours per day for most days of the week. The micronutrient intakes of the majority of these jockeys were also low (i.e. <67% of recommended intake). Mean calculated energy availability (EA) over two training days and one rest day was 27.1±16.7 kcal/kg FFM and regarded as low (i.e.<30kcal/kg/FFM). Furthermore, the majority of apprentices (88%) had a low EA on the training days. Ninety one percent of the jockeys reported the use of one or more weight control method including food avoidance (81%), restricting food intake and skipping meals (67%), exercising to sweat (48%) and using the sauna (43%). The top three reported side effects from making weight included thirst (80%), hunger (75%) and tiredness (75%). CONCLUSION: In conclusion, the results of the present study showed that the majority of South African apprentice jockeys are practicing weight control methods, specifically restricting energy and food intake, to control their weight. This was supported by the mean low dietary energy intake and sub-optimal mean energy availability. These apprentice jockeys are therefore at risk for long-term health consequences including low bone mineral density.Master

Determining percentage body fat of male South African jockey apprentices irrespective of hydration status

Objective: The aim was to determine the most appropriate field techniques to measure %BF when both euhydrated and dehydrated. Design: A cross-sectional descriptive study was undertaken. Setting: South Africa. Subjects: 17 male apprentice jockeys (mean age 18.8 ± 1.7 years). Outcome measures: Agreement of %BF results determined using predictive equations based on skinfold thickness measurements and bioelectric impedance analysis (BIA) with that of the reference method, euhydrated deuterium dilution (eDD). Results: The mean %BF according to eDD was 9.5 ± 2.8%. The skinfold equations by Slaughter et al. (1988) for ages 8–18 years in either hydration state, Durnin and Womersley using either Siri or Brožek et al. for ages 17–19 years when dehydrated only, and the Van Loan et al. BIA equation when euhydrated only were the most acceptable methods. Conclusion: Regardless of hydration status, the skinfold equation by Slaughter et al. is recommended for jockey apprentices 18 years and younger. For those > 19 years, the hydration state must be confirmed prior to measurement. If euhydrated, the Van Loan et al. BIA equation is recommended and if dehydrated the Durnin and Womersley using either Siri or Brožek et al. is recommended

Inspiration Geschichte : Publikation der Arbeitsgemeinschaft des Kunsthandwerks Hamburg e.V.

AlternativeReviewe

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. US National Institutes of Health and Operation Warp Spee